Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report

Journal of the Pancreas

Volumn 10, Issue 5, 2009, Pages 523-527

  Bharthuar, Anubha ^a   Pearce, Lori ^a   Litwin, Alan ^a   LeVea, Charles ^a   Kuvshinoff, Boris ^a   Iyer, Renuka ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Gemcitabine; Kidney neoplasms; Pancreatic neoplasms; Sunitinib

Indexed keywords

BILIRUBIN; GEMCITABINE; SUNITINIB;

ABDOMINAL PAIN; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DECOMPRESSION; DRUG TOLERABILITY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; HUMAN TISSUE; HYPERTENSION; JAUNDICE; KIDNEY CARCINOMA; LAPAROSCOPY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; REPEATED DRUG DOSE; STENT; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; NEOPLASMS, MULTIPLE PRIMARY; PANCREATIC NEOPLASMS; PYRROLES; TREATMENT OUTCOME;

EID: 70349275752     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-63.
2. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 2002;26:1542-52.
3. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000;119:1087-95.
4. Beisland C, Talleraas O, Bakke A, Norstein J. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int 2006;97:698-702.
5. Sato S, Shinohara N, Suzuki S, Harabayashi T, Koyanagi T. Multiple primary malignancies in Japanese patients with renal cell carcinoma. Int J Urol 2004;11:269-75.
6. Rabbani F, Grimaldi G, Russo P. Multiple primary malignancies in renal cell carcinoma. J Urol 1998;160:1255-9.
7. Society AC. Cancer Facts and Figures Atlanta, Ga. American Cancer Society 2008.
8. Alexakis N, Bosonnet L, Connor S, Ellis I, Sutton R, Campbell F, et al. Double resection for patients with pancreatic cancer and a second primary renal cell cancer. Dig Surg 2003;20:428-32.
9. Olgyai G, Haulik L, Olah A. [Double resection for synchronous pancreatic and renal cell cancer - case report]. Magy Seb 2004;57:287-9.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
11. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
12. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-40.
13. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-8.
14. Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O'Reilly E, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol (Meeting Abstracts) 2007;25:LBA4509-.
15. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
16. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
17. O'Reilly EM, Niedzwiecki, D. D., R. Hollis, T. S. Bekaii-Saab, T. Pluard, A. Duffy, F. Overcash, S. P. Ivy, R. M. Goldberg. A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J Clin Oncol 2008;26.
18. Brell JM, Bokar J. A., Cooney M. M. , S. S. Krishnamurthi, J. Gibbons, C. J. Nock, P. Savvides, E. Batts, S. P. Ivy, A. Dowlati. Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. J Clin Oncol 2008;26.
19. Michaelson M, Schwarzberg A, Ryan D, McDermott D, Shapiro G, Tye L, et al. A phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. ASCO Genitourinary Cancers Symposium 2008;Abstract No 362.
20. Pandya S, Mier J, Cho D, McDermott D. The role of adding gemcitabine at time of sunitinib resistance in patients with metastatic renal cell cancer. ASCO Genitourinary Cancers Symposium 2008.